2059Background: The prognosis for patients (pts) with recurrent glioblastoma is still poor with a median survival between 3 and 6 months. Angiogenesis is crucial for glioblastoma (Gb) growth, and anti-vascular endothelial growth factor agents are widely used in recurrent Gb pts. Following the results of BELoB trial we explored the efficacy of carmustine plus bevacizumab considering the prognostic value of several biomarkers. Methods: This retrospective study included 59 adult pts with histologically confirmed Gb who were treated with carmustine (BCNU 80 mg/m2 days 1-3 every 8 weeks) in combination with bevacizumab (10 mg/kg every 15 days) as a second line regimen. Response rate (RR), 6-month progression free survival (PFS6), progression-free survival (PFS) and overall survival (OS) were assessed according to CD133 mRNA expression, MGMT methylation (pMGMT) and IDH1/2, p53 and EGFRvIII mutation status. Results: The median age was 43-yo (23-70 years), 35 patients were male (59%), 78% of cases were treated wi...